In addition, depletion of RUNX2 expression improves gemcitabine cytotoxicity in the pancreatic cancer cell lines AsPC-1 (p53-negative) and MiaPaCa-2 (p53-mutated pancreatic cancer), potentially through stimulation of TAp63- and TAp73-dependent cell death, respectively [70,71]. Here, TP53 is linked to pancreatic neoplasm.